Sputnik V, Sputnik Light booster effective against Omicron: Study

Earlier this month, Russian President Vladimir Putin praised Sputnik V efficiency against Omicron

India is the leading production hub for production of Sputnik vaccine
Press Trust of India Moscow
3 min read Last Updated : Dec 22 2021 | 6:01 PM IST

Russia's Sputnik-V vaccine and its one-shot version Sputnik Light booster demonstrates high virus-neutralising activity (VNA) against the highly-contagious Omicron variant of COVID-19, providing a strong defence against severe disease and hospitalisation, according to a study.

The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), an investor in Sputnik V and Sputnik Light vaccines, in an article titled Sputnik Light booster after Sputnik V vaccination induces robust neutralising antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant said that the vaccine is expected to provide a strong defence against severe disease and hospitalisation.

The study was conducted using sera with a long period after vaccination (more than 6 months after vaccination) as an indicator of Sputnik V's long-lasting protection, Sputnik-V said in a statement on Wednesday.

Sputnik V elicits a strong and long-lasting T-cell response, and as 80% of epitopes in the spike protein are not affected by the mutations in the Omicron variant, Sputnik V is expected to provide long-lasting protection against severe disease by Omicron, it said.

Sputnik V's long-lasting T-cell immunity contributes to 80% efficacy against Delta on months 6-8, the statement said.

Sputnik Light as a booster significantly increases virus neutralising activity against Omicron based on sera 2-3 months after revaccination.

Virus neutralising activity against Omicron 2-3 months after a Sputnik Light booster in this preliminary laboratory study is higher than VNA against the wild-type virus 6 months after Sputnik V vaccination.

Based on these data the expected efficacy of Sputnik V with Sputnik Light booster against Omicron infection could be more than 80%, as Sputnik V showed the efficacy of more than 80% against wild-type virus 6 months after vaccination, according to the study.

Individuals who are 100% revaccinated with Sputnik Light as a booster developed neutralising antibodies against Omicron and demonstrated their high level 2-3 months after the revaccination.

Sputnik Light booster is expected to provide strong protection against infection, severe disease and hospitalisation by Omicron.

Sputnik Light booster is recommended to strengthen the efficacy of vaccines against Omicron. Boosting by Sputnik Light can strengthen and lengthen the quickly waning efficacy of many vaccines in light of the combined Delta and Omicron challenge.

Sputnik Light is a universal booster to other vaccines, including Sputnik V. Sputnik V and Sputnik Light were developed on the basis of a safe and well-studied over 30 years of technology and have not been associated with rare serious side effects as myocarditis or pericarditis, the study said.

Sputnik Light has already been registered in more than 20 countries as a standalone vaccine and a universal booster to other vaccines helping to increase their efficacy (including in Argentina, UAE, Bahrain, the Philippines, and San Marino).

Sputnik V has been authorised in 71 countries with a total population of over 4 billion people.

Earlier this month, Russian President Vladimir Putin praised Sputnik V efficiency against omicron.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Dec 22 2021 | 6:01 PM IST

Next Story